此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HBO After Thrombectomy for AIS With LVO

2026年6月2日 更新者:Beijing Tiantan Hospital

HyperBaric Oxygen Therapy After ACute Thrombectomy in Acute Ischemic strOke Due to Large Vessel occlusioN

The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.

研究概览

详细说明

This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial with a 1:1 ratio, comparing the effect of hyperbaric oxygen therapy plus standard medical treatment versus standard medical treatment alone after endovascular treatment in patients with acute large vessel occlusion ischemic stroke. The primary outcome is modified Rankin Scale (mRS) score distribution at 90 days (±14 days) after randomization.

研究类型

介入性

注册 (估计的)

420

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100071
        • 招聘中
        • Beijing Tiantan Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Age 18~80 years;
  2. Clinically diagnosed as acute large vessel occlusive ischemic stroke, suitable for and received endovascular treatment according to current clinical guidelines;
  3. The onset of stroke or the last normal time to the time of endovascular treatment ≤ 24 hours;
  4. Pre-stroke mRS score of 0 or 1;
  5. Baseline NIHSS score before endovascular treatment ≥ 6 points in the anterior circulation or ≥10 points in the posterior circulation;
  6. CTA, MRA, or DSA angiography before endovascular treatment confirmed occlusion of large vessels (internal carotid artery, middle cerebral artery M1 segment, basilar artery), consistent with symptoms and signs;
  7. The corresponding anterior circulation ASPECTS score or posterior circulation pc-ASPECTS score ≥ 6 points;
  8. The pontine midbrain index (PMI) of patients with acute basilar artery occlusion ≤3;
  9. Patients or their family members sign the informed consent form.

Exclusion Criteria:

  1. Patients with extensive bleeding or severe increase in infarct area, midline displacement (>0.5cm), etc. during endovascular treatment, who plan to undergo bone valve decompression or ventricular drainage;
  2. Known bleeding risk factors, including coagulation factor deficiency, or receiving anticoagulant therapy, INR>3.0 or APTT > 3 times normal or platelet count less than 50×10⁹/L;
  3. Severe hepatic or renal dysfunction (severe hepatic dysfunction refers to ALT or AST > 3 times the upper limit of the normal range, severe renal dysfunction refers to serum creatinine Cr >1.5 times the upper limit of the normal range);
  4. Females of pregnancy, or positive pregnancy test prior to randomization;
  5. Severe persistent and medication-uncontrollable hypertension (systolic blood > 185 mmHg or diastolic blood > 110 mmHg)
  6. Baseline blood glucose of <50 mg/dL (2.78 mmol/L) or >400 mg/dL (22.20 mmol/L);
  7. The oxygen required to maintain 95% of peripheral arterial oxygen saturation (SaO2) under the current medium-term management guidelines > 3L/min;
  8. End-stage disease other than the nervous system, life expectancy < 90 days;
  9. Participating in other drug or medical device clinical trials;
  10. CT or MR suggests intracranial tumors (other than meningiomas) or other high-risk intracranial vascular malformations;
  11. Patients with anemia, polycythemia or other conditions requiring urgent oxygen;
  12. Unable to cooperate with hyperbaric oxygen therapy, or have other diseases that are not suitable for hyperbaric oxygen therapy (such as active/chronic obstructive pulmonary disease, acute respiratory distress syndrome, tension pneumothorax, tension pneumocephalus, etc.).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:标准医疗治疗
According to the current guideline "2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association" "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023", they receive standard medical treatment and monitoring (including antithrombotic drugs, lipid-lowering drugs, blood pressure management, etc.), not entering the hyperbaric oxygen chamber for treatment.
其他名称:
  • 药物治疗
实验性的:Hyperbaric oxygen therapy+ standard medical treatment

The first treatment was initiated within 24 hours after enrollment. The treatment plan is: in a medical multi-person air pressurized chamber, the treatment pressure is 0.2 MPa, the pressurization time is 30 minutes, the mask inhales 100% oxygen for 60 minutes, and the decompression time is 30 minutes. Once a day, once on the 1st, 2nd, and 3rd days after enrollment (i.e., within the 24-hour, 48-hour, and 72-hour time window), a total of 3 times. Vital signs such as blood pressure, heart rate, and blood oxygen saturation will be monitored before, during, and after each hyperbaric oxygen therapy.

The rest of the treatment is standard medical treatment and monitoring according to the current clinical guideline "2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association" "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023".

其他名称:
  • 家庭影院

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
mRS score distribution at 90 days
大体时间:90±14 days after randomization
Modified Rankin Scale (mRS) score distribution at 90 days (±14 days) after randomization
90±14 days after randomization

次要结果测量

结果测量
措施说明
大体时间
mRS score 0-1 at 90 days after randomization
大体时间:90±14 days after randomization
90±14 days after randomization
mRS score 0-2 at 90 days after randomization
大体时间:90±14 days after randomization
90±14 days after randomization
Change in NIHSS score from baseline to 24 hours postoperatively
大体时间:24 hours after endovascular treatment
24 hours after endovascular treatment
Change in NIHSS score from baseline to 5 days postoperatively (after the end of hyperbaric oxygen therapy)
大体时间:5 days after endovascular treatment
5 days after endovascular treatment
Recanalization rate of responsible arteries at 24-48h postoperatively
大体时间:24-48 hours after endovascular treatment
24-48 hours after endovascular treatment
Volume of cerebral infarction on the 5th postoperative day or at discharge (after the end of hyperbaric oxygen therapy)
大体时间:5 days after endovascular treatment or at discharge
assessed by MRI or CT
5 days after endovascular treatment or at discharge
Total number of days in hospital
大体时间:From date of randomization until date of hospital discharge, assessed up to 30 days.
Number of days hospitalized (from randomization to hospital discharge)
From date of randomization until date of hospital discharge, assessed up to 30 days.
Quality of life EQ-5D-5L score at 90 days after randomization
大体时间:90±14 days after randomization
The EuroQoL 5-Dimensions 5-Level (EQ-5D-5L) is a five-dimension, five-level health-related quality of life instrument. Based on the Chinese value set, its utility score ranges from -0.391 to 1.000, with higher scores indicating better outcomes.
90±14 days after randomization
mRS score 0-1 at 1 year after randomization
大体时间:1 year ±30 days after randomization
1 year ±30 days after randomization
mRS score 0-2 at 1 year after randomization
大体时间:1 year ±30 days after randomization
1 year ±30 days after randomization

其他结果措施

结果测量
措施说明
大体时间
All-cause death 90 days after randomization
大体时间:90±14 days after randomization
90±14 days after randomization
Symptomatic intracranial hemorrhage at 18-36 hours after randomization
大体时间:18-36 hours after randomization
Symptomatic intracranial hemorrhage was defined according to the Heidelberg classification of hemorrhage
18-36 hours after randomization
Any type of intracranial hemorrhage at 18-36 hours after randomization
大体时间:18-36 hours after randomization
confirmed by CT or MRI images
18-36 hours after randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ning Ma, MD、Beijing Tiantan Hospital
  • 首席研究员:Qiuhong Yu, MD、Beijing Tiantan Hospital
  • 首席研究员:Yuesong Pan, MD、Beijing Tiantan Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月1日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2026年5月18日

首先提交符合 QC 标准的

2026年6月2日

首次发布 (实际的)

2026年6月4日

研究记录更新

最后更新发布 (实际的)

2026年6月4日

上次提交的符合 QC 标准的更新

2026年6月2日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅